Does Victoza cause anxiety? This is a question some people with type 2 diabetes ask when considering or taking this GLP-1 receptor agonist medication. Victoza (liraglutide) is widely prescribed in the UK to help manage blood glucose levels, but concerns about potential mental health effects, including anxiety, occasionally arise. Whilst anxiety is not listed as a recognised side effect in official UK regulatory documentation, understanding the relationship between Victoza and mental wellbeing is important. This article examines the evidence, explores possible contributing factors, and provides guidance on when to seek medical advice.
Quick Answer: Anxiety is not listed as a recognised side effect of Victoza (liraglutide) in UK regulatory documentation, though some patients report anxiety-like symptoms that may be related to other factors such as hypoglycaemia or the stress of managing diabetes.
Victoza (liraglutide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus in adults and children aged 10 years and above. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of a naturally occurring hormone in the body that helps regulate blood sugar levels.
The mechanism of action of Victoza is multifaceted. Primarily, it stimulates insulin secretion from the pancreas in a glucose-dependent manner, meaning it only triggers insulin release when blood glucose levels are elevated. This reduces the risk of hypoglycaemia when used as monotherapy, though this risk increases when combined with insulin or sulphonylureas. Additionally, Victoza suppresses glucagon secretion, a hormone that raises blood sugar, and slows gastric emptying, which helps moderate the rise in blood glucose after meals. These combined effects contribute to improved glycaemic control in people with type 2 diabetes.
Victoza is administered as a once-daily subcutaneous injection, typically in the abdomen, thigh, or upper arm. The dose is gradually increased over several weeks to minimise gastrointestinal side effects, starting at 0.6 mg daily and potentially increasing to 1.2 mg or 1.8 mg depending on individual response and tolerability. According to NICE guidance (NG28), GLP-1 receptor agonists like Victoza are typically considered as part of triple therapy regimens, often with specific BMI criteria, and should be continued only if HbA1c falls by ≥11 mmol/mol (1.0%) and weight reduces by ≥3% at 6 months.
Whilst Victoza is primarily prescribed for diabetes management, it also promotes modest weight loss in many patients, which can be beneficial given the strong association between obesity and type 2 diabetes. Victoza is not indicated for type 1 diabetes or diabetic ketoacidosis. Understanding how Victoza works helps contextualise potential side effects, including questions about its impact on mental health and anxiety.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereAnxiety can manifest through a wide range of physical, emotional, and cognitive symptoms, and recognising these whilst taking Victoza is important for appropriate management. Common anxiety symptoms include persistent worry or apprehension, restlessness, difficulty concentrating, irritability, muscle tension, and sleep disturbances. Physical manifestations may include palpitations, sweating, trembling, shortness of breath, dizziness, or gastrointestinal upset.
It is crucial to note that anxiety is not listed as a recognised side effect in the official Summary of Product Characteristics (SmPC) for Victoza approved by the Medicines and Healthcare products Regulatory Agency (MHRA). The most commonly reported adverse effects of Victoza are gastrointestinal in nature, including nausea, vomiting, diarrhoea, and constipation, particularly during the initial titration period. However, the absence of anxiety from official documentation does not mean patients never experience it whilst taking the medication.
Several factors may contribute to anxiety-like symptoms in people taking Victoza. Hypoglycaemia (low blood sugar), though less common with GLP-1 agonists as monotherapy, can produce symptoms that mimic anxiety, including tremor, sweating, palpitations, and confusion. The risk of hypoglycaemia increases when Victoza is used with insulin or sulphonylureas. If you experience anxiety-like symptoms, checking your blood glucose level can help determine if hypoglycaemia might be the cause. Additionally, the stress of managing a chronic condition like diabetes itself is a significant risk factor for anxiety and depression. Research from Diabetes UK indicates that people with diabetes have an increased likelihood of experiencing depression and anxiety compared to the general population.
If you notice new or worsening anxiety symptoms after starting Victoza, it is important to monitor the timing and context of these symptoms. Keep a diary noting when symptoms occur, their severity, and any potential triggers such as missed meals, changes in blood glucose levels, or other life stressors. This information will be valuable when discussing your concerns with your healthcare provider.
If you suspect you are experiencing side effects from Victoza, you can report these through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).
The relationship between GLP-1 receptor agonists and mental health remains an area of ongoing research and clinical interest. Whilst there is no established causal link between Victoza and anxiety specifically, it is important to understand the broader context of mental health considerations with this class of medications.
Some patients have reported mood changes whilst taking GLP-1 agonists, though these are not consistently documented across clinical trials. Anecdotal reports include feelings of low mood, irritability, or emotional lability. However, it is challenging to determine whether these experiences are directly attributable to the medication, related to the underlying condition, or influenced by other factors such as lifestyle changes, weight loss, or concurrent medications.
Recent pharmacovigilance reviews by regulatory authorities including the MHRA and European Medicines Agency have examined reports of suicidal ideation and self-harm with GLP-1 receptor agonists. To date, no causal association has been established, though monitoring continues and patients should remain vigilant for changes in mood or thoughts.
Some early-stage research suggests that GLP-1 receptor agonists might have effects on brain function, as GLP-1 receptors are present in the brain. Animal studies have indicated possible roles in mood regulation and neuroprotection. However, these findings remain exploratory, and there is currently insufficient clinical evidence to suggest established mental health benefits in humans.
It is worth noting that weight loss, which can occur with Victoza, may itself impact mood and mental wellbeing in some individuals. Changes in body image, energy levels, and metabolic state can all influence psychological health. Additionally, the gastrointestinal side effects commonly experienced with Victoza—particularly persistent nausea—can contribute to reduced quality of life and potentially affect mood.
The NHS and NICE emphasise the importance of holistic diabetes care that addresses both physical and mental health. Healthcare professionals should routinely screen for depression and anxiety in people with diabetes, regardless of their medication regimen. If you are experiencing mental health concerns whilst taking Victoza, this should be taken seriously and discussed with your healthcare team, who can help determine the most appropriate course of action, which may include psychological support, medication review, or referral to specialist services.
Knowing when to contact your GP or diabetes care team about anxiety symptoms whilst taking Victoza is essential for maintaining both your physical and mental wellbeing. You should seek medical advice if you experience new or worsening anxiety that interferes with your daily activities, relationships, or quality of life.
Seek prompt medical attention if you experience:
Severe or persistent anxiety that does not improve or worsens over time
Panic attacks characterised by sudden, intense fear with physical symptoms such as chest pain, difficulty breathing, or feeling faint
Thoughts of self-harm or suicide—this requires urgent assessment; contact your GP immediately, call NHS 111 for urgent advice, call 999 or attend A&E if you're at immediate risk of harm, or contact the Samaritans (116 123) for emotional support
Symptoms that may indicate hypoglycaemia, including tremor, sweating, confusion, or palpitations, especially if accompanied by anxiety-like feelings—check your blood glucose and follow standard hypoglycaemia treatment (15-20g of fast-acting carbohydrate) if levels are low
Significant mood changes, including persistent low mood, loss of interest in activities, or feelings of hopelessness
When discussing your concerns with your healthcare provider, be prepared to provide detailed information about your symptoms, including when they started in relation to beginning Victoza, their frequency and severity, and any factors that seem to trigger or relieve them. Bring your blood glucose monitoring records, as patterns of hypoglycaemia or poor glycaemic control may be relevant.
Your healthcare team may consider several approaches, including reviewing your current medication regimen to ensure Victoza is the most appropriate choice for you, checking for potential drug interactions, optimising your diabetes management to reduce blood glucose fluctuations, or referring you for psychological support such as cognitive behavioural therapy (CBT), which has good evidence for treating anxiety disorders according to NICE guidelines.
It is important not to stop taking Victoza abruptly without medical guidance, as this could affect your diabetes control. Your doctor can help you weigh the benefits and risks of continuing the medication and explore alternative treatment options if necessary. Remember that effective diabetes management and mental health support can and should go hand in hand, and seeking help is a positive step towards comprehensive wellbeing.
If you believe you are experiencing side effects from Victoza, you can report these through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.
No, anxiety is not listed as a recognised side effect in the official UK Summary of Product Characteristics for Victoza. The most common adverse effects are gastrointestinal, including nausea, vomiting, and diarrhoea.
Hypoglycaemia (low blood sugar), which can occur when Victoza is used with insulin or sulphonylureas, may produce symptoms that mimic anxiety such as tremor, sweating, and palpitations. Checking blood glucose levels can help identify if hypoglycaemia is the cause.
Contact your GP or diabetes care team to discuss your symptoms, particularly if anxiety is new, worsening, or affecting your daily life. Do not stop taking Victoza without medical guidance, and report suspected side effects through the MHRA Yellow Card scheme.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
